January 5, 2018 / 1:18 PM / Updated 5 minutes ago BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus Reuters Staff 1 Min Read 
Jan 5 (Reuters) - Xencor Inc: 
* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS 
* XENCOR INC - INITIATE PHASE 3 TRIAL IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)